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OBJECTIVE — To estimate the prevalence and incidence of diabetes, clinical characteristics,
and risk factors for chronic complications among Navajo youth, using data collected by the
SEARCH for Diabetes in Youth Study (SEARCH study).
RESEARCH DESIGN AND METHODS — The SEARCH study identified all prevalent
cases of diabetes in 2001 and all incident cases in 2002–2005 among Navajo youth. We esti-
mated denominators with the user population for eligible health care facilities. Youth with
diabetes also attended a research visit that included questionnaires, physical examination, blood
and urine collection, and extended medical record abstraction.
RESULTS — Diabetes is infrequent among Navajo youth aged 10 years. However, both
prevalence and incidence of diabetes are high in older youth. Among adolescents aged 15–19
years, 1 in 359 Navajo youth had diabetes in 2001 and 1 in 2,542 developed diabetes annually.
The vast majority of diabetes among Navajo youth with diabetes is type 2, although type 1
diabetes is also present, especially among younger children. Navajo youth with either diabetes
type were likely to have poor glycemic control, high prevalence of unhealthy behaviors, and
evidence of severely depressed mood. Youth with type 2 diabetes had more metabolic factors
associated with obesity and insulin resistance (abdominal fat deposition, dyslipidemia, and
higher albumin-to-creatinine ratio) than youth with type 1 diabetes.
CONCLUSIONS — Our data provide evidence that diabetes is an important health problem
for Navajo youth. Targeted efforts aimed at primary prevention of diabetes in Navajo youth and
efforts to prevent or delay the development of chronic complications among those with diabetes
are warranted.
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D ata on the burden of diabetes in U.S.Native American youth are limited,with the exception of the Pima In-
dians of Arizona (1,2). In adults, Pima In-
dians have the highest occurrence of type
2 diabetes in the world, and very high
rates have been reported in many other
U.S. Indian tribes (3). Although type 2 dia-
betes has traditionally been viewed as a dis-
order of adults, an alarming two- to
threefold increase in the prevalence of type
2 diabetes has been documented over the
last 30 years among Pima Indian youth, in
parallel with changes in obesity (1).
The Navajo Nation is the largest land
area assigned primarily to a Native Amer-
ican jurisdiction within the U.S., occupy-
ing all of northeastern Arizona and
extending into Utah and New Mexico. Di-
abetes in Navajo people has been reported
since the 1960s, with recent reports in
adults suggesting estimates of type 2 dia-
betes two to four times those of non-
Hispanic white (NHW) populations and
rising over the past 20–30 years (4,5).
However, there are no population-based
studies of diabetes occurrence in Navajo
youth, although earlier reports (6,7) sug-
gested that type 2 diabetes in youth was a
relatively rare condition. It has been as-
sumed that diabetes in Native American
youth is primarily type 2 diabetes (8).
Therefore, the relative contribution of au-
toimmune-mediated type 1 diabetes to
the overall burden of diabetes among Na-
vajo youth has not been systematically
studied, although type 1 diabetes has
been clinically recognized. Finally, there
are no published reports on clinical char-
acteristics and risk factors for diabetes-
related complications. We report here
population-based estimates of prevalence
and incidence of diabetes by type, clinical
characteristics, and risk factors for
chronic complications.
RESEARCH DESIGN AND
METHODS — The SEARCH for Dia-
betes in Youth Study (SEARCH study) as-
certained diabetes in youth aged 20
years in 2001 and continues to ascertain
incident cases since 2002 (9) in geograph-
ically defined populations in Ohio, Wash-
ington, South Carolina, and Colorado and
among health plan enrollees in Hawaii
and southern California. Coordinated by
the Colorado center, diabetes cases were
also identified among Navajo youth.
The SEARCH-Navajo population
The SEARCH-Navajo study sought to
identify all prevalent cases of diabetes in
2001 and all incident cases in 2002–
2005. The study was approved by the In-
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dian Health Services (IHS) directors,
directors of tribally operated health care
facilities, and the Navajo Nation Human
Research Review Board (NNHRRB) and
was Health Insurance Portability and Ac-
countability Act compliant. The popula-
t ion denominator was defined as
individuals aged 20 years who self-
identified themselves as Navajo and had
at least one visit in the preceding 3 years
to an eligible health care facility. Health
care facilities include six Navajo area HIS
units (Chinle, Crownpoint, Fort Defi-
ance, Gallup, Kayenta, and Shiprock) and
two tribally operated facilities (Tuba City
and Winslow).
Estimation of prevalence and
incidence
The 2001 prevalence denominator in-
cluded 98,014 users of health care facili-
ties. Potential case subjects had one or
more outpatient visits or hospitalizations
coded for diabetes (ICD-9 codes 250.0–
250.9) and were aged 20 years on 31
December 2001. For 2002–2005 inci-
dence estimates, the denominator in-
cluded eligible youth with at least one
visit in the preceding 3 calendar years.
The sum of the annual denominators was
used as average total denominator (n 
380,633 person-years) over the 4-year
period. Potential case subjects had one or
more diabetes-related ICD-9 codes, were
diagnosed in 2002–2005, and were aged
20 years on 31 December of the year of
diagnosis.
Case validation and collection of
core variables
All eligible potential case subjects were
validated using medical records. Less
than 50% of case subjects identified using
the IHS database had diabetes; miscoding
was the most common reason for invalid
case reports. For all validated cases, core
demographic and diagnostic information
was obtained from medical records. The
clinical diabetes type assigned by the
health care provider was categorized as
type 1 (combining types 1, 1a, and 1b)
and type 2 diabetes. Youth with other
types (including hybrid, secondary diabe-
tes, unknown, and missing) were ex-
cluded (n  3).
Additional data collection
Youth were asked to participate in a re-
search visit and they and/or their parent
provided written informed consent ac-
cording to the guidelines established by
the NNHRRB. Questionnaires collected
socioeconomic and medical history. In-
formation about dietary intake, physical
activity, smoking, and depressive symp-
toms was collected from participants aged
10 years. Diet was assessed by a food
frequency questionnaire modified for
administration in youth and capturing
culturally specific foods (10). Physical ac-
tivity questions were from the Youth Risk
Behavioral Surveillance System question-
naire (11). Depressive symptoms were as-
sessed using the Center for Epidemiologic
Studies–Depression Scale (CES-D) (12).
A CES-D score 24 was used as evidence
of severely depressed mood (13).
Blood was drawn after an overnight
fast under conditions of metabolic stabil-
ity (14) for measurement of GAD65 anti-
bodies and fasting and stimulated
C-peptide (mixed-meal challenge), which
were used to further characterize the pro-
vider-assigned diabetes type. A1C, fasting
glucose, and lipids (total and HDL and
LDL cholesterol, triglycerides, apoli-
poprotein B, and LDL particle density)
were also measured (9). Glycemic control
was categorized according to American
Diabetes Association guidelines (15) as
adequate when A1C 8% and poor when
A1C 9.5%. A spot-urine sample was
collected in the morning, and urinary al-
bumin and creatinine were measured. An
albumin-to-creatinine ratio 30 g/mg
(16) was considered elevated.
For youth aged 3 years, a physical
examination included height, weight, and
waist circumference; evaluation for acan-
thosis nigricans; and measurement of sys-
tolic and diastolic blood pressure (9).
Obesity was defined as a BMI 95th per-
centile, and overweight was a BMI in the
85th to 95th percentile (17). Weight
and height were compared with U.S.
standards (17) to calculate normalized
z-scores. Waist circumference was mea-
sured using the National Health and Nu-
trition Examination Survey protocol (17).
Elevated blood pressure levels were
present if systolic or diastolic blood pres-
sure were 95th percentile for age, sex,
and height. Hypertension was estimated
based on elevated blood pressure levels or
antihypertensive medication use (18).
Statistical analyses
Comparisons were made between sub-
groups of diabetes types (type 1 and type
2 diabetes) to determine whether charac-
teristics differed. Fisher’s exact tests for
categorical variables and ANOVA for con-
tinuous variables were used. Linear or
logistic regression was used to adjust for
differences in age and duration of dia-
betes between type 1 and type 2 diabetic
patients. Variables that were not nor-
mally distributed were logarithmically
transformed. Given the descriptive na-
ture of these analyses, we used an 
level of 0.05 and did not correct for
multiple comparisons.
RESULTS — Table 1 shows the num-
ber of Navajo youth with prevalent
(2001) and incident diabetes (2002–
2005), prevalence and incidence rates,
and their distribution by age-group. A to-
tal of 92 youth aged 20 years had dia-
betes in 2001, and 66 were newly
diagnosed in 2002–2005. The prevalence
of diabetes in Navajo youth was low un-
der the age of 10 years (0.11 per 1,000)
and high (2.78 per 1,000) in youth aged
15–19 years. Similarly, the incidence of
diabetes was low in children aged 10
Table 1—Prevalence and incidence of diabetes among Navajo youth
Charcteristics
Age (years) 0–9 10–14 15–19
Prevalence (2001)
Population 47,553 27,107 23,354
Cases 5 22 65
Prevalence per 1,000 0.11 0.81 2.78
95% CI* 0.04–0.25 0.54–1.23 2.18–3.55
Population/case 9,510 1,232 359
Incidence (2002–2005)
Person-years 178,793 102,693 99,147
Cases 4 23 39
Rate per 100,000 person-years 2.24 22.40 39.34
95% CI* 0.87–5.75 14.93–33.61 28.78–53.76
Population/case 44,698 4,465 2,542
*95% CIs are calculated using an inverted-score test from the binomial distribution (24).
Diabetes in Navajo youth
S142 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, MARCH 2009
years (2.24 per 100,000 per year) but
high in adolescents aged 15–19 years
(39.34 per 100,000 per year).
Overall, 18 prevalent case subjects
had type 1 (19.6%) and 74 had type 2
(80.4%) diabetes. There were 10 type 1
(15.2%) and 56 type 2 (84.8%) diabetic
patients incident in 2002–2005. Figure 1
shows type-specific estimates of preva-
lence (upper panel) and incidence (lower
panel), according to age-group and sex.
Estimates of type 1 diabetes prevalence
and incidence are low and vary little with
age and sex. These data indicate that type
1 diabetes is present in all age-groups and
both sexes but is a rare condition among
Navajo children and adolescents. In con-
trast, type 2 diabetes is exceptionally rare
in youth aged 10 years (only one indi-
vidual with type 2 diabetes) but very com-
mon in adolescents aged 15–19 years.
Among adolescents aged 15–19 years, the
prevalence of type 2 diabetes was 2.63
and 2.07 per 1,000. In the same age-
group, the incidence rates of type 2 dia-
betes were 38.16 and 32.42 per 100,000
per year in female and male subjects, re-
spectively. Incidence rates of type 2 dia-
betes increased with age (P  0.04 for
youth aged 15–19 years vs. youth aged
10–14 years) and female subjects aged
10–14 years were more likely to have
type 2 diabetes than male subjects (P 
0.04).
Table 2 presents characteristics asso-
ciated with provider-defined diabetes
type. Of 158 registered patients, 83 par-
ticipated in the research visit. Youth with
type 2 diabetes were older and had a
shorter duration of diabetes than those
with type 1 diabetes. Almost 50% of
youth with clinical type 1 diabetes had
positive GAD65 antibody titers, while
only 20% of those with type 2 diabetes
had such antibodies (P  0.05). Mean
fasting and stimulated C-peptide levels
were significantly higher in youth with
type 2 diabetes, even after adjusting for
differences in age and diabetes duration,
reflecting important differences in resid-
ual insulin secretory capacity and likely
different pathophysiologic mechanisms
in youth with type 2 versus type 1 diabe-
tes. As expected, youth with type 2 diabe-
tes had significantly higher BMI (33.6 vs.
23.5 kg/m2) and BMI z scores (1.8 vs.
0.7), as well as higher prevalence of obe-
sity (67.7 vs. 12.5%). More youth with
type 2 diabetes had evidence of insulin
resistance, as manifested by presence of
acanthosis nigricans (64.1 vs. 17.7%),
than youth with type 1 diabetes. Youth
with both type 2 and type 1 diabetes had
a very strong family history of diabetes
(92.2 and 76.5%, respectively). The pres-
ence of diabetic ketoacidosis at diabetes
onset was nonsignificantly greater among
youth with type 1 diabetes (40 vs. 14.3%
in type 2 diabetes), suggesting a more
acute onset possibly caused by more ag-
gressive etiopathogenesis. While all but
one youth with type 1 diabetes were on
insulin therapy at study visit, only 26.4%
of those with type 2 diabetes were treated
with insulin (nine patients with insulin
only and another five with insulin and
metformin). Most patients with type 2 di-
abetes were treated with metformin (over-
all 67.9%); however, 15.1% had no
pharmacologic treatment for diabetes (on
average 3.5 years after diagnosis).
Table 3 presents risk factors for
chronic complications among Navajo
youth by diabetes type. No major differ-
ences between type 1 and type 2 diabetes
youth were noted in terms of glycemic
control, health-related behaviors (smok-
ing, physical activity, total fat, and fruit
and vegetable intake) and socioeconomic
status (family income and education).
Nevertheless, Navajo youth with both di-
abetes types were very likely to have poor
glycemic control (53.3 and 43.3% of
Figure 1—Prevalence (per 1,000, upper panels) and incidence (per 100,000 per year, lower panels) of diabetes among Navajo Nation youth, by
diabetes type, age-group, and sex.
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youth with type 1 and type 2 diabetes,
respectively, had A1C levels 9.5%) and
a high prevalence of unhealthy behaviors
(smoking, physical inactivity, and high
dietary fat). In addition, 14.3% of type 1
and 21.9% of type 2 diabetic youth had
evidence of severely depressed mood.
Youth with type 2 diabetes had more met-
abolic factors associated with obesity and
insulin resistance (higher abdominal fat
deposition, dyslipidemia [higher triglyc-
erides, low HDL cholesterol, and more
small dense LDL cholesterol particles],
and higher albumin-to-creatinine ratio).
Although mean blood pressure levels and
the prevalence of elevated blood pressure
were similar in type 1 and type 2 diabetes,
more patients with type 2 diabetes were
on antihypertensive medication (ACE in-
hibitors), resulting in a nonsignificantly
higher prevalence of hypertension (35.3
vs. 12.5%; P  0.1).
CONCLUSIONS — The SEARCH-
Navajo study is the first population-based
study to provide estimates of diabetes
prevalence and incidence among Navajo
youth. We found that diabetes was infre-
quent in youth aged 10 years; however,
both prevalence and incidence of diabetes
were high in older youth, especially ado-
lescents aged 15–19 years. In this age-
group, 1 in 359 Navajo youth had
diabetes in 2001 and 1 in 2,542 devel-
oped diabetes annually. The majority of
diabetes among Navajo youth was type
2 diabetes, although type 1 (autoim-
mune) diabetes was present, especially
among younger children. Of all racial/
ethnic groups in the SEARCH study, Na-
vajo youth aged 15–19 years had the
greatest risk of type 2 diabetes (14). In
contrast, the rates of type 1 diabetes in
Navajo youth were the lowest of all
SEARCH study racial/ethnic groups (14).
Data on prevalence of diabetes in Na-
vajo youth are minimal. There are virtu-
ally no data on diabetes incidence, and no
differentiation according to diabetes type
was published. An earlier study (7) of 160
Navajo youth aged 12–19 years found
that the prevalence of impaired glucose
tolerance or undiagnosed diabetes was
8%. In 1999, Kim et al. (6) screened 234
high school student volunteers with oral
glucose tolerance tests. One student was
found to have diabetes (0.4%) and 3%
had impaired glucose tolerance or im-
paired fasting glucose. Recent efforts by
Navajo area IHS investigators are focused
on a more comprehensive assessment of
the current burden of diabetes in Navajo
youth (C.A., personal communication).
The majority of data on diabetes among
American Indian youth come from popu-
lation-screening studies, such as the Pima
Indian study (1). The prevalence of type 2
diabetes among Pima Indians of Arizona
is much higher than reported here for Na-
vajo youth (37.8 and 53.1 per 1,000
among Pima male and female subjects
aged 15–19 years, respectively, vs. 2.07
and 2.63 per 1,000 in Navajo male and
female subjects aged 15–19 years, respec-
tively). Similarly, the incidence rates of
type 2 diabetes are 10-fold higher
among Pima youth aged 5–14 years
(331.9 per 100,000 per year) than among
Navajo youth (19). These data may reflect
population differences in risk for type 2
diabetes but are also partly due to system-
atic screening for case ascertainment
among the Pima Indians.
Using the IHS database, Acton et al.
(20) recently found that the prevalence of
all diabetes among American Indian/
Alaska Native youth aged 15–19 years
was 5.4 per 1,000, a figure much closer to
that reported here (2.78 per 1,000), al-
though this study did not conduct case
validation through medical record ab-
straction. Our experience is that 50% of
cases identified through the Navajo IHS
database in youth aged 20 years were
not valid diagnoses of diabetes, due
largely to miscoding. Another recent
study (21) conducted between 1999 and
2001 among American Indian youth aged
20 years in Montana and Wyoming
used methods similar to the SEARCH
study (case identification through the IHS
database followed by medical record val-
idation). In these populations, the preva-
lence and incidence of diabetes were
similar to those reported for Navajo Indi-
ans (prevalence estimates were 0.7 and
1.3 per 1,000 and incidence rates were
Table 2—Characteristics of diabetes type among Navajo youth with diabetes (2001 prevalent







Current age (years) (means  SD) 15.3  4.5 18.0  2.8 0.03
Diabetes duration (years) (means  SD) 6.0  4.7 3.5  2.2 0.047
GAD antibody positive n (%)	 7 (46.7) 12 (20.3) 0.05
Fasting C-peptide (ng/ml)
Unadjusted (means  SD) 0.7  0.9 3.8  2.3 0.0001
Adjusted (means  SE)* 1.3  0.6 3.6  0.3 0.002
Stimulated C-peptide (area under the curve) (ng/ml)
Unadjusted (means  SD) 2.0  3.2 11.6  7.0 0.0001
Adjusted (means  SE)* 4.4  1.9 11.0  0.8 0.003
BMI (means  SD) 23.5  5.3 33.6  9.1 0.0001
BMI z score (means  SD) 0.7  0.9 1.8  1.1 0.0004
Weight n (%)	
Underweight 1 (6.3) 1 (1.6)
Normal 9 (56.2) 9 (14.5) 0.0001
Overweight 85th to 95th percentile 4 (25.0) 10 (16.1)
Obese 95th percentile 2 (12.5) 42 (67.7)
Acanthosis Nigricans n (%)	 3 (17.7) 41 (64.1)
Diabetes therapy (current) n (%)	
Insulin 15 (88.2) 9 (17.0)
Metformin 0 (0.0) 31 (58.5) 0.0001
Both 1 (5.9) 5 (9.4)
None 1 (5.9) 8 (15.1)
Diabetic ketoacidosis at onset n (%)	† 2 (40.0) 3 (14.3) 0.2
Family history of diabetes n (%)	
Yes 13 (76.5) 59 (92.2) 0.087
No 4 (23.5) 5 (7.8)
Family history of diabetes  mother, father, sibling, or grandparent with positive family history. *Adjusted
for age and duration. †Medical record evidence of hyperglycemia and one or more of the following: 1) blood
bicarbonate 15 mmol/l or pH 7.25 (venous) or 7.30 (arterial or capillary), 2) ICD-9 code 250.1 at
discharge, and 3) a diagnosis of diabetic ketoacidosis in the medical records.
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Table 3—Clinical, metabolic, behavioral, and sociodemographic risk factors for chronic complications among Navajo youth with diabetes, by
diabetes type (2001 prevalent and 2002–2005 incident cases combined)
Variable Clinical type 1 diabetes Clinical type 2 diabetes P
n 17 66
A1C (%) (means  SD) 9.8  2.3 9.0  2.8 0.3
Glycemic control (A1C) n (%)	
8% 3 (20.0) 26 (43.3)
8–9.5% 4 (26.7) 8 (13.3) 0.197
9.5% 8 (53.3) 26 (43.3)
Waist circumference
Unadjusted (means  SD) 88.4  16.3 110.7  24.2 0.0008
Adjusted (means  SE)* 94.9  6.6 109.0  3.0 0.07
High waist circumference n (%)	
90th percentile for age and sex 4 (25.0) 52 (82.5) 0.0001
Systolic blood pressure (means  SD) 114.5  10.6 118.2  12.5 0.3
Diastolic blood pressure (means  SD) 70.3  10.4 73.3  9.2 0.2
Elevated blood pressure n (%)	† 2 (12.5) 9 (14.5) 0.8
Taking antihypertensive medication n (%)	‡ 0 (0.0) 14 (26.4) 0.016
Hypertension prevalence n (%)	§ 2 (12.5) 22 (35.5) 0.1
Triglycerides (mg/dl)
Unadjusted median (interquartile range)	 109.5 (78.0) 147.0 (137.0) 0.03
Adjusted median (interquartile range)	* 99.2 (25.9) 162.3 (24.3) 0.06
High triglycerides (110 mg/dl) n (%)	
Unadjusted 7 (50.0) 42 (73.7) 0.1
Adjusted* (48.7) (74.1) 0.1
HDL cholesterol (mg/dl)
Unadjusted (means  SD) 55.9  16.3 41.7  10.4 0.005
Adjusted (means  SE)* 53.2  3.4 42.3  1.5 0.008
Low HDL cholesterol (40 mg/dl) n (%)	
Unadjusted (means  SD) 2 (13.3) 26 (44.1) 0.04
Adjusted* (15.4) (41.1) 0.1
LDL cholesterol (mg/dl)
Unadjusted (means  SD) 109.9  38.8 101.4  35.1 0.4
Adjusted (means  SE)* 110.6  10.9 101.2  4.8 0.5
High LDL cholesterol (100 mg/dl) n (%)	
Unadjusted 6 (42.9) 26 (45.6) 0.9
Adjusted* (46.6) (43.7) 0.9
LDL cholesterol density (Rf)
Unadjusted (means  SD) 0.27  0.02 0.25  0.03 0.02
Adjusted (means  SE)* 0.27  0.01 0.25  0.005 0.07
Apolipoprotein B (mg/dl)
Unadjusted median (interquartile range)	 94.0 (39.0) 84.0 (57.0) 0.9
Adjusted median (interquartile range)	* 87.6 (23.7) 87.9 (13.9) 0.7
High albumin-to-creatinine ratio (30 g/mg) n (%)	
Unadjusted 2 (13.3) 17 (28.8) 0.3
Adjusted (means  SE)* (5.6) (31.5) 0.05
Smoking n (%)	
Never 10 (66.7) 26 (39.4)
Former 2 (13.3) 23 (34.8) 0.15
Current 3 (20.0) 17 (25.8)
Physical activity (means  SD)
Average number of days per week 3.7  2.5 3.0  2.0 0.2
Physically active n (%)	
0–2 days/week 5 (33.3) 33 (50.0)
3–7 days/week 10 (66.7) 33 (50.0) 0.3
Percent calories from fat (means  SD)
Total fat 36.3  7.7 36.4  6.9 0.9
Saturated fat 12.5  2.7 12.5  2.9 0.9
Fruits and vegetables (servings/day) (means  SD) 2.8  2.2 4.0  2.5 0.1
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5.8 and 23.3 per 100,000 per year for
type 1 and type 2 diabetes, respectively).
Our study also provides important
descriptive information on characteristics
of diabetes type, as well as risk factors for
chronic complications. Disturbingly, 40–
50% of youth with diabetes had poor gly-
cemic control. In addition, there was a
high prevalence of obesity and related
cardiometabolic disturbances (central fat
deposition, dyslipidemia, and hyperten-
sion), especially among type 2 diabetic
youth (Table 3). No such information was
previously available in youth with diabe-
tes, although one of the earliest studies (6)
of nondiabetic Navajo youth found them
to have higher BMI levels, with higher
triglyceride and lower HDL cholesterol
levels than NHW youth. Coupled with
high prevalence of unhealthy behaviors
(smoking, high-fat diets, and sedentary
lifestyles) and lower socioeconomic sta-
tus (Table 3), these findings may trans-
late to an increased prevalence of
cardiovascular disease in the future as
these youth mature.
There are a several potential limita-
tions to this study. We did not include
Navajo Indians who received services
from non-IHS providers. Because the IHS
facilities provide universal health care
coverage to all American Indian/Alaskan
Native people, we do not believe that our
ascertainment approach excluded an im-
portant number of youth with diabetes.
We did not attempt to assess how much
undiagnosed diabetes existed through
screening. We may, therefore, have un-
derestimated the true risk of type 2 diabe-
tes in Navajo youth. Similar to other
population-based studies (1,22), our
analyses utilized diabetes type assign-
ments made by health care providers. Di-
abetes type was further characterized in a
subset of Navajo youth participating in
the research visit. With a clinical diagno-
sis of type 1 diabetes, GAD65 antibody
positivity was present in almost 50% of
individuals (Table 2), similar to other ra-
cial/ethnic groups participating in the
SEARCH study (14). The GAD65-
negative participants with type 1 diabetes
may have lost GAD positivity, may be
positive for other autoantibodies, or may
have other causes of insulin deficiency.
With a clinical diagnosis of type 2 diabe-
tes, 20.3% of Navajo participants had
positive GAD65 antibodies, which is sim-
ilar to other racial/ethnic groups participat-
ing in the SEARCH study (14), as well as
other smaller U.S. studies (23). The role of
autoantibody positivity in the etiology and
natural evolution of diabetes among youth
with a clinical phenotype of type 2 diabetes
requires further exploration.
Our data provide strong evidence that
diabetes is an important health problem
for Navajo youth. Because young people
with diabetes will have more years of dis-
ease burden and an increased risk of de-
veloping diabetes-related complications
early in life, targeted efforts aimed at pri-
mary prevention of diabetes in Navajo
youth and efforts to prevent or delay the
development of chronic complications
among those who already developed dia-
betes are warranted.
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